MPNs | Clinical

Data Support Momelotinib as a Differentiated Approach to Treating Myelofibrosis

January 22, 2021

JAK inhibitors designed for the treatment of myelofibrosis address the splenic response and constitutional symptoms associated with the disease, but the agents are inherently myelosuppressive and can exacerbate anemia and thrombocytopenia.

Fedratinib Appears Safe for Long-Term Treatment of Intermediate- to High-Risk Myelofibrosis

January 12, 2021

Twenty-four or more cycles of fedratinib was well-tolerated in patients with intermediate- or high-risk myelofibrosis treated in either the phase 1/2 TED12015 study or the phase 1 TED12037 study. The long-term safety and tolerability results of fedratinib.

Conditioning with Thiotepa-busulfan-fludarabine Improves Outcomes for Patients with MF Undergoing ASCT

December 28, 2020

When patients with myelofibrosis who required hematopoietic stem cell transplant received a conditioning regimen of thiotepa, busulfan, and fludarabine along with 2 two alkylating agents, the subsequent transplants were nearly all successful.

Improving Patient Outcomes With Ruxolitinib in Advanced Myelofibrosis

December 16, 2020

Srdan Verstovsek, MD, PhD, discusses how research and future clinical trials can better determine the benefit of ruxolitinib as treatment of patients with myelofibrosis, which is often measured in improvements in the quality of life and spleen reductions.

Surveillance for Second Primary Malignancy Recommended in Select Patients With Myelofibrosis Treated With Ruxolitinib

December 15, 2020

Patients with myelofibrosis who receive ruxolitinib appear to face a higher risk of second primary malignancy; these risks are suggested to be even higher in men and patients with a history of arterial thrombosis and prolonged hydroxycarbamide exposure.

Evaluation of RESPONSE Trials Guides Use of Ruxolitinib in Polycythemia Vera

December 13, 2020

During a Targeted Oncology Case Based Peer Perspectives event, Andrew Kuykendall, MD, assistant member, Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, discussed the use of ruxolitinib as treatment of 67-year-old patients with polycythemia vera.

Luspatercept Demonstrates Efficacy and Tolerable Safety in Patients With MDS/MPN-RS-T

December 07, 2020

Luspatercept demonstrated clinical efficacy and a tolerable safety profile in patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis who were enrolled in the MEDALIST trial.